Hans Lee, MD

Director, Myeloma Research; Chair, Myeloma Research Executive Committee; SCRI Oncology Partners

Dr. Hans Lee joined SCRI in 2025 as the director of myeloma research where he provides scientific leadership and oversight for SCRI’s comprehensive myeloma clinical trial menu across its vast network of more than 200 locations.

Dr. Lee joined SCRI from The University of Texas MD Anderson Cancer Center in Houston where he served as the Director of Multiple Myeloma Clinical Research and Associate Professor within the Department of Lymphoma/Myeloma. Dr. Lee received his undergraduate degree from Purdue University and his Doctor of Medicine degree from Indiana University School of Medicine followed by residency (internal medicine) at Washington University School of Medicine/Barnes-Jewish Hospital and clinical fellowship (hematology/oncology) where he was the Chief Hematology Fellow at University of Texas MD Anderson Cancer Center.

Dr. Lee is dual board certified in hematology and medical oncology.  He has extensive experience as a principal investigator for both investigator-initiated and industry-sponsored early phase clinical trials in multiple myeloma and AL amyloidosis and has previously served on the National Comprehensive Cancer Network Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenstrom’s Macroglobulinemia Panel. Dr. Lee’s’ research has been funded by the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) and highlighted in 125+ peer-reviewed publications.

In addition to his leadership role at SCRI, Dr. Lee serves as a medical oncologist at SCRI Oncology Partners in Nashville, Tenn.